Unleash the Power of Oligo CustomizationSynoligo enables many scientific discoveries through high quality oligonucleotide synthesis.

Broken String Biosciences is building a technology platform that accelerates the characterization of novel genome editing technologies. This will unlock the next wave of cell & gene therapies. INDUCE-seq™ is a game changing technology for the characterization of genome breaks in cell & gene therapy applications.

Responsible and accountable for identifying, developing, and growing Synthego's Cell Therapy target client base and Synthego’s Synthetic sgRNA GMP manufacturing portfolio.

Hired into Eurofins as a KEL - Eurofins Genomics LLC is a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatic services for academic and industrial research. The company’s strengths are its strong customer orientation, fast service and high quality products including a series of advanced oligonucleotide design tools.The Louisville Quality Management System of Eurofins Genomics has been certified to ISO 9001 and ISO 13485 standards by BSI Group Americas, Inc.

Sale of Rebus Biosystems 1st Esper automated spatial omics platform along with 6 StellarVision systems using Stellaris RNA~Fish probes as interrogation probes. Provided expert advice and coordinated customer sales for Optical Biosystem's novel Synthetic Aperture Optics (SAO) based StellarVision High Throughput imaging platforms and Rebus Biosystems Esper automated spatial transcriptomics platform.

Responsible for successful Concept to Selection (Initial and secondary submissions) to initial contact for contract negotiations - DTRA BAA Proposal Number HDTRA114-AMD3-CBA-01-2-0061 "Rapid Quantitative In-Situ Protein and Gene Expression Platform Technologies for Host Response""Congratulations your proposal, HDTRA114-AMD3-CBA-01-2-0061, entitled Rapid Quantitative In-Situ Protein and Gene Expression Platform Technologies for Host Response Biomarker Methods and Analysis, was evaluated and selected in accordance with the criteria specified in Section 6.3., and Attachment 10 of the Broad Agency Announcement (BAA), Solicitation Number: HDTRA1-14-CHEM-BIO-BAA, Chemical Biological Technologies Department.Debriefing Summary: The offeror proposes a comprehensive approach to build an integrated rapid diagnostic platform for single cell-level quantification of host biomarker expression. They aim to combine the expertise of multiple research groups on RNA FISH biomarker probe sets, magnetic micropore microfluidic chips for specific isolation of cells from whole blood, synthetic aperture microscopy (StellarVision) etc. to build and test their first prototype. The proposed approach is highly innovative and technically sound with a very small risk of being unsuccessful. Members of this interdisciplinary team and facilities are qualified to perform the proposed work. The strongest aspects of this proposal are that offerors combine strong scientific approaches, and leverage the expertise of multiple research groups . The proposed costs are reasonable to realize the technical approach offered.Congratulations! The Defense Threat Reduction Agency (DTRA) is providing notification that your Proposal Number HDTRA114-AMD3-CBA-01-2-0061 entitled "Rapid Quantitative In-Situ Protein and Gene Expression Platform Technologies for Host Response" submitted under Broad Agency Announcement (BAA) HDTRA1-14-CHEM-BIO-BAA Amendment #3 has been tentatively selected for contract award.

Primarily responsible for recognizing and effecting new business opportunities for the company. Most recently, in licensed all critical IP for Stellaris RNA ~FISH (iceFISH, SNPFISH, turboFISH and StellarVision Synthetic Aperture Optics (SAO based) product lines while Seeding Stellaris and StellarVision alpha/beta test sites, partnerships and sales. Additionally, involved in establishing and managing sales, marketing, international distribution channels/partners for the company’s products, determining new markets and applications for company products, negotiating licensing and supply agreements of Biosearch IP to Corporate clients, scouting of possible synergistic relationships with other companies, including possible acquisition targets, and serves as Biosearch’s corporate representative for establishing Corporate relationships. Responsible for Global Sales, Strategic and Corporte Business Development for all Biosearch products including Stellaris RNA FISH and StellarVision products, DNA Synthesis and purification columns, Black Hole Quencher™ Cal Fluor/Quasar product lines and (RUO, IVD, cGMP) PCR primers and probes for the Gene Expression, SNP Genotyping, Biomarker and DNA MicroArray Markets.

Primarily Responsible for National Sales and Business Development - PCR Primers and Probes for the Gene Expression and SNP Genotyping Markets incorporating a Secondary Focus on all other Custom Modified DNA Synthesis Opportunities and platforms.

Responsible for Start-up of Merck (KGAa) Technical Center in the USA Which Included Selling of Software, Contract GMP Manufacturing Services, Training of E.M. Marketing and Sales Team, Generation of Merck Resin Sorbant Applications Along with Set Up of Alpha and Beta Test Sites for Merck (KGAa) Products in the USA.

Responsible for product positioning, teaching and sales, of Pancuronim, Norcuron, Tice BCG, and Organon's oral contraceptive product lines at USCF, Stanford and other teaching hospitals in the San Francisco Bay Area. Promoted from a local regional sales representative for 200 to 300 percent increase in sales year over year.

Start-Up of a Second Generation rt-Pa Core Biochemistry Group. Investigation of Combinatorial Mutant rt-Pa Interactions (Binding, Stimulation and Inhibition) with Various Blood Proteins and Cells through High Throughput Screening Assay Development and Validation. Teamed with Five Other Researchers in the Bench to GMP Cloning, Purification and Scale-Up of rt-Pa, Biotechnology's First Block Buster Drug.Publication -Downstream Processing of Proteins: Recent Advances. John R. Ogez, James G. Hodgdon, Marc P. Beal and Stuart E. Builder, Biotechnology Advances, Volume 7 (1989) 467-488.

U.C. DAVIS DEPARTMENT OF CHEMISTRYResearch Assistant: Cloning and Sequencing of Chimp, Gorilla and Human Pseudo Alpha and Alpha Globin Genes. Publication -Intergenic DNA Sequences Flanking the Pseudo Alpha Globin Genes of Human and Chimpanzee. Ikuhisa Sawada, Marc Beal, Che-Kun James Shen, Barbara Chapman, Allan Wilson and Carl Schmid. Nucleic Acids Research, Volume 11, Number 22 (1983) 8087 - 8101.CROCKER NUCLEAR LAB (U. C. DAVIS)Research Assistant: Assimilation of N13 into plants. HPLC and Analysis of radioactive intermediates.U.C. DAVIS MEDICAL CENTERResearch Assistant: Isolation and Purification of Histones (H2A and H2B).